Five-year study shows outlets have been exaggerating efficacy, safety and longevity of the drug
Get our morning and afternoon news emails, free app or daily news podcast
Many media stories about ketamine as a treatment for psychiatric disorders such as depression “go well beyond the evidence base” by exaggerating the efficacy, safety and longevity of the drug or by overstating the risks, an analysis has found.
Researchers examined 119 articles about ketamine and mental illness published by major print media in Australia, the US and UK over a five-year period. They found articles peaked in 2019, when the US Food and Drug Administration approved a ketamine-derived nasal spray known as esketamine for treatment-resistant depression.
About Author
More Stories
Nearly 200,000 Canadians sign petition to revoke Musk’s citizenship
Trump says Putin will accept European peacekeepers in Ukraine
‘You dream about such things’: Brit who discovered missing pharaoh’s tomb may have unearthed another